HomeNewsDrug Discovery & Development

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml oral solution

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml oral solution

Marksans Pharma announced that UK MHRA has granted Market Authorisation to the company's wholly-owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.

The therapeutic use of the product is for the treatment of depressive illness and other mental/mood disorders

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.

Read more on:
Marksans Pharma UK MHRA
More news about: drug discovery & development | Published by Sudeep Soparkar | January - 24 - 2023

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology